TY - JOUR
T1 - The human crisis in cancer
T2 - a Lancet Oncology Commission
AU - Rodin, Gary
AU - Feldman, Amalya
AU - Trapani, Dario
AU - Skelton, Mac
AU - Unger-Saldaña, Karla
AU - Essue, Beverley
AU - Pihlak, Rille
AU - Walshe, Catherine
AU - Rosa, William E.
AU - Banegas, Matthew P.
AU - Zambrano-Lucio, Miguel
AU - Salah Daood, Rawaz
AU - Aggarwal, Ajay
AU - Dewachi, Omar
AU - Shapiro, Gilla K.
AU - Munisamy, Murallitharan
AU - Rajah, Harenthri Devy Alagir
AU - Atreya, Shrikant
AU - Dhyani, Vijay Shree
AU - Kong, Yek Ching
AU - Mathew, Mebin
AU - Ochoa-Dominguez, Carol Y.
AU - Rao, Arathi Prahallada
AU - Rao, Seema Rajesh
AU - Simha, Srinagesh
AU - Preston, Nancy
AU - Lam, Wendy Wing Tak
AU - Davis, Hanae
AU - Zimmermann, Camilla
AU - Namisango, Eve
AU - Ntizimira, Christian
AU - Smyth, Elizabeth
AU - Li, Madeline
AU - Salins, Naveen
AU - Bhoo-Pathy, Nirmala
AU - Sullivan, Richard
N1 - Publisher Copyright:
© 2025 Elsevier Ltd.
PY - 2025/12
Y1 - 2025/12
N2 - Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes improving, the systems designed to deliver care increasingly fall short in addressing the emotional, relational, and existential dimensions of cancer. Although examples of compassionate and attentive care can be found in every setting, patients and families across global contexts continue to report being unheard, unsupported, and, at times, actively harmed by care structures that prioritise technical precision over human presence. This Lancet Oncology Commission proposes that the human crisis of cancer is not defined by pathology, mortality, or cause, but by the erosion of meaning, connection, and compassion in the experience of cancer. This crisis is shaped by what is present and what is absent: the presence of fragmented, costly, and impersonal systems and the absence of human connection, psychological safety, and relational care. It is a crisis that spans delivery, mental health, palliative care, research, and education—one that is not peripheral to oncology's progress but central to its failures. The impacts of this crisis are felt most acutely by those already made vulnerable by inequity, discrimination, and economic precarity, but it is a system-level failure that ripples across every context, from the most resource-rich to the most resource-constrained settings. Addressing this crisis will require more than good intentions; it will demand confronting the structural incentives and ideologies that have devalued the relational foundations of cancer care. This Commission identifies a growing imbalance between technological innovation and the human dimensions of cancer care. As the field has increasingly prioritised biopharmaceutical development, genomic precision, and market-driven efficiencies, it has often neglected core practices that uphold dignity, alleviate suffering, and build trust.
AB - Amid unprecedented scientific progress in oncology, a growing body of evidence reveals a parallel and profound crisis in the human experience of cancer care. Despite overall survival outcomes improving, the systems designed to deliver care increasingly fall short in addressing the emotional, relational, and existential dimensions of cancer. Although examples of compassionate and attentive care can be found in every setting, patients and families across global contexts continue to report being unheard, unsupported, and, at times, actively harmed by care structures that prioritise technical precision over human presence. This Lancet Oncology Commission proposes that the human crisis of cancer is not defined by pathology, mortality, or cause, but by the erosion of meaning, connection, and compassion in the experience of cancer. This crisis is shaped by what is present and what is absent: the presence of fragmented, costly, and impersonal systems and the absence of human connection, psychological safety, and relational care. It is a crisis that spans delivery, mental health, palliative care, research, and education—one that is not peripheral to oncology's progress but central to its failures. The impacts of this crisis are felt most acutely by those already made vulnerable by inequity, discrimination, and economic precarity, but it is a system-level failure that ripples across every context, from the most resource-rich to the most resource-constrained settings. Addressing this crisis will require more than good intentions; it will demand confronting the structural incentives and ideologies that have devalued the relational foundations of cancer care. This Commission identifies a growing imbalance between technological innovation and the human dimensions of cancer care. As the field has increasingly prioritised biopharmaceutical development, genomic precision, and market-driven efficiencies, it has often neglected core practices that uphold dignity, alleviate suffering, and build trust.
UR - https://www.scopus.com/pages/publications/105023322864
UR - https://www.scopus.com/pages/publications/105023322864#tab=citedBy
U2 - 10.1016/S1470-2045(25)00530-3
DO - 10.1016/S1470-2045(25)00530-3
M3 - Article
C2 - 41192457
AN - SCOPUS:105023322864
SN - 1470-2045
VL - 26
SP - e628-e670
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 12
ER -